How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Novel Anti-Tuberculosis Compounds

Organization name

PROvendis GmbH



The resurgence of tuberculosis, caused primarily by Mycobacterium tuberculosis (Mtb), and the appearance of multi-drug and extensively drug resistant Mtb strains strengthen the need for new drugs with alternative modes of action. The interaction between the mycobacterial thioredoxin reductase (TrxR) and its substrate thioredoxin (Trx) is a promising new drug target for the treatment of tuberculosis, since Mtb lacks the common glutathione system and the mycobacterial TrxR shows a substantial difference in sequence, mechanism and structure to human TrxRs. It was shown that TrxR is essential for thiol redox homeostasis and genetic inactivation in vivo eradicates Mtb during acute and chronic mouse infections (Lin et al., PLoS Pathog. 2016).

In order to further improve the bioactivity of promising compounds, researchers of the TU Dortmund University have focused on optimizing the physico-chemical properties that are important for permeability, since M. tuberculosis shows an unusual thick and impermeable cell wall.

Commercial Opportunities

The technology is offered for licensing and further therapeutic development.

Competitive Advantages

  • Novel class of compounds that inhibit a novel target with potential to overcome resistance problems of M. tuberculosis to other drugs
  • Viability of infected macrophages is not affected
  • Increased bioactivity by optimized permeability through the cell wall of M.┬átuberculosis

Current Status

The researcher are preparing the further development towards mice studies to confirm in vivo efficacy, as well as ADME-Tox studies. In case of interest we are pleased to inform you about the patent status.

Relevant Publications

Koch, O., et al. (2013) Identification of M. tuberculosis thioredoxin reductase inhibitors based on high-throughput docking using constraints J. Med. Chem. 56(12): 4849-59.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback to "Novel Anti-Tuberculosis Compounds"


latest entries

latest entries